Please login to the form below
Poxel
This page shows the latest Poxel news and features for those working in and with pharma, biotech and healthcare.
Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease
Treatment can help patients with advanced disease, companies say. Emboldened by new clinical data, French biotech Poxel and partner Metavant are planning a phase 3 programme in the US and Europe ... Imeglimin is thought to work against mitochondrial
Latest news
-
After Axovant shock, Roivant pens diabetes deal with Poxel
Hard on the heels of the Axovant news, parent company Roivant announced that it had signed a development and licensing deal with French biotech Poxel for imeglimin, a candidate originally discovered ... Poxel says imeglimin is in a new class of oral
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Kardex
Kardex is a global industry partner for intralogistics solutions and a leading supplier of automated storage solutions and material handling...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
